Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: A case report

被引：6

作者：

Pelosi E. ^{[1
]}

Skanjeti A. ^{[2
]}

Cistaro A. ^{[1
]}

Arena V. ^{[1
]}

机构：

[1] IRMET PET Center, Via Onorato Vigliani

[2] Nuclear Medicine Unit, University of Turin, 10126 Turin, Corso Bramante

来源：

Journal of Medical Case Reports | / 2卷 / 1期

关键词：

Positron Emission Tomography; Positron Emission Tomography Study; Bicalutamide; Enlarge Liver; High Blood Level;

D O I：

10.1186/1752-1947-2-99

中图分类号：

学科分类号：

摘要：

Introduction: Castleman's disease is a rare lymphatic polyclonal disorder that is characterised by unicentric or multicentric lymph node hyperplasia and non-specific symptoms and signs including fever, asthenia, weight loss, enlarged liver and abnormally high blood levels of antibodies. Case presentation: We present the case of a 74-year-old man with Castleman's disease. The disease was detected with a contrast-enhanced computed tomography (CT) scan and a fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT study; diagnosis was made with histopathology. After treatment with surgical excision followed by chemotherapy, the disease response was evaluated using both diagnostic techniques. However, only the PET study was able to identify the spread of the disease to the abdominal lymph nodes, which were both enlarged and normal size, and, after treatment, to evaluate the disease response. Conclusion: Based on the results of previous case reports and on those of the present study, it seems that Castleman's disease has a high glucose metabolic activity. Therefore, the use of PET can be considered appropriate in order to stage or restage the disease and to evaluate the response of the disease to treatment. © 2008 Pelosi et al; licensee BioMed Central Ltd.

引用

共 7 条

[1]

Castleman B., Towne V.W., Case records of the Massachusetts General Hospital: Case 40011, N Engl J Med, 250, pp. 26-30, (1954)

[2]

Dham A., Peterson B.A., Castleman disease, Curr Opin Hematol, 14, pp. 354-359, (2007)

[3]

Murphy S.P., Nathan M.A., Karwal M.W., FDG-PET appearance of pelvic Castleman's disease, J Nucl Med, 38, pp. 1211-1212, (1997)

[4]

Kunishima S., Taniguchi H., Koh T., Yamaguchi A., Yamagishi H., F-18 fluorodeoxyglucose positron emission tomography in mesenterial Castleman's lymphoma, Clin Nucl Med, 26, pp. 789-790, (2001)

[5]

Blockmans D., Maes A., Stroobants S., Bobbaers H., Mortelmans L., FDG positron emission tomographic scintigraphy can reveal Castleman's disease as a cause of inflammation, Clin Nucl Med, 26, pp. 975-976, (2001)

[6]

Reddy M.P., Graham M.M., FDG positron emission tomographic imaging of thoracic Castleman's disease, Clin Nucl Med, 28, pp. 325-326, (2003)

[7]

Enomoto K., Nakamichi I., Hamada K., Inoue A., Higuchi I., Sekimoto M., Mizuki M., Hoshida Y., Kubo T., Aozasa K., Hatazawa J., Unicentric and multicentric Castleman's disease, Br J Radiol, 80, 949, pp. 24-26, (2007)

← 1 →